Santarus Inc., of San Diego, and Pharming Group, of Leiden, the Netherlands, said the FDA accepted for filing the biologics license application (BLA) for Ruconest (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema

Ambrx Inc., of San Diego, and Zhejiang Medicine Co

Madera Biosciences Inc., of San Diego, said it was awarded follow-on funding of $298,500 from the Alzheimer's Drug Discovery Foundation to further develop the firm's small-molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease

Trius Therapeutics Inc., of San Diego, published results of clinical and animal studies showing that its antibiotic TR-701 does not interact with monamine oxidase, meaning that if approved it could potentially be taken with antidepressants whose use is limited with agents that inhibit MAO

Biotie Therapies Corp., of Turku, Finland, obtained an exclusive option to acquire Neurelis Inc., of San Diego

Oncosec Medical Inc., of San Diego, signed a sponsored research agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics

Apricus Biosciences Inc., of San Diego, said its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction, has been approved through the European decentralized procedure

Cardium Therapeutics Inc., of San Diego, held its annual meeting of stockholders and temporarily adjourned the meeting to allow additional time for stockholders to vote on two remaining issues related to a proposed reverse stock split and a charter amendment, which were favored by a majority of shares voted but which also require a majority of all outstanding shares, including unvoted shares...Regen BioPharma, of San Diego, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc., submitted

Biotie Therapies Corp., of Turku, Finland, obtained an exclusive option to acquire Neurelis Inc., of San Diego

Metreleptin, a recombinant analogue of human hormone leptin, was developed by San Diego-based Amylin Pharmaceuticals Inc., which was acquired in a joint buyout by BMS and AstraZeneca last year. (See BioWorld Today, July 3, 2012

Acadia Pharmaceuticals Inc., of San Diego, said Allergan Inc., of Irvine, Calif., advanced an additional product candidate as a potential new treatment for glaucoma

Halozyme Therapeutics Inc., of San Diego, said the European Commission granted partner Baxter International Inc., of Deerfield, Ill., marketing authorization in all European Union (EU) member states for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adults with primary and secondary immunodeficiencies

has acquired Actagene Oncology Inc., both of San Diego...Sorrento Therapeutics Inc. (STI), of San Diego, said the National Institute of Allergy and Infectious Diseases renewed the second year of a two-year Phase I fast-track advanced technology small business technology transfer research (STTR) grant to support the development of human antibody therapeutics to combat Staphylococcus aureus infections, including methicillin-resistant S

AnaptysBio Inc., of San Diego, disclosed a contract award from the U.S

Sorrento Therapeutics Inc., of San Diego, and Igdrasol Inc., of Irvine, Calif., said they acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean firm, to Cynviloq (marketed as Genexol-PM in South Korea) in the 27 countries of the European Union

Institut de Recherches Servier, of Paris, inked a nonexclusive collaboration to use the enhanced spine platform (ESP) technology developed by Afraxis Inc., of San Diego, to discover central nervous system (CNS) drugs

Arena Pharmaceuticals Inc., of San Diego, said partner Eisai Inc., of Woodcliff Lake, N.J., will be able to launch obesity drug Belviq (lorcaserin) next month, following completion of a Drug Enforcement Agency (DEA) review that deemed the drug as a Schedule IV substance

Vical Inc., of San Diego, said preclinical evaluations of its Vaxfectin adjuvant in combination with cell culture-derived seasonal and pandemic influenza vaccines from Baxter International Inc., of Deerfield, Ill., were published online in Human Vaccines & Immunotherapeutics

Cardium Therapeutics Inc., of San Diego, said the April 2013 issue of Molecular Therapy published a paper, titled "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors